Arrhythmogenic cardiomyopathy: what blood can reveal?

Research output: Contribution to journalArticle


Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve the diagnosis, prognosis prediction, and management of ACM patients.

Original languageEnglish
JournalHeart Rhythm
Publication statusAccepted/In press - Jan 1 2018



  • Arrhythmogenic right ventricular cardiomyopathy
  • Biomarkers
  • Blood
  • Genetics
  • Heart failure
  • Inflammation
  • microRNA
  • Plasma
  • Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this